Sugi Predict

Sugi Predict / Compounds / SCHEMBL733742

SCHEMBL733742

SCHEMBL733742

C=C1CCN(C(=O)OC(C)(C)C)CC1O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ESR2 Q92731 1/20 0.42
▸ NR1H2 P55055 2/20 0.41
▸ MAPT P10636 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GPR119 Q8TDV5 2/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ PTPN2 P17706 1/20 0.38
▸ PTPN1 P18031 1/20 0.38
▸ PTPN6 P29350 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL734541 1.00 USP2 (0.42) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL2337486 0.84 USP2 (0.42) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL136365 0.84 NR1H2 (0.43) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL28296118 0.84 NR1H2 (0.43) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL22468373 0.84 NR1H2 (0.43) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL15227433 0.83 USP2 (0.41) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL31561924 0.83 USP2 (0.44) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL31372297 0.83 USP2 (0.44) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL12908934 0.83 USP2 (0.44) USP2SMN1; SMN2ESR2NR1H2MAPT
SCHEMBL31715320 0.80 USP2 (0.39) USP2SMN1; SMN2ESR2NR1H2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025184391-A9 COVALENT INHIBITORS AND USES THEREOF ARRAKIS THERAPEUTICS, INC. (US) 2025-10-30 — — WO disclosed
US-20250215012-A1 IKZF2 DEGRADERS AND USES THEREOF UNIV MICHIGAN (US) 2025-07-03 — — US disclosed
US-20250195484-A1 CEREBLON LIGANDS AND USES THEREOF UNIV MICHIGAN (US) 2025-06-19 — — US disclosed
US-20250122171-A1 Substituted Amine Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. 2025-04-17 — — US disclosed
CN-119731179-A IKZF2 degradation agent and application thereof 密歇根大学董事会 2025-03-28 — — CN disclosed
WO-2025064534-A1 SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2025-03-27 — — WO disclosed
EP-4499649-A1 IKZF2 DEGRADERS AND USES THEREOF Regents of the University of Michigan (US) 2025-02-05 — — EP disclosed
WO-2024192064-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) 2024-09-19 — — WO disclosed
WO-2024083208-A1 KIF18A PROTEIN INHIBITOR 杭州邦顺制药有限公司 2024-04-25 — — WO disclosed
CN-117917405-A KIF18A protein inhibitors 杭州邦顺制药有限公司 2024-04-23 — — CN disclosed
EP-0615977-B1 Spiro piperidines and homologs which promote release of growth hormone MERCK & CO INC (US) 2002-07-03 — — EP disclosed
US-6013652-A ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIHISTAMINES MERCK & CO., INC. (US) 2000-01-11 — — US disclosed
US-5962462-A COMPOUNDS WHICH INHIBIT THE ENTRY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INTO TARGET CELLS; DELAYING THE ONSET OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS). MERCK & CO., INC. (US) 1999-10-05 — — US disclosed
WO-1998025605-A1 SPIRO-SUBSTITUTED AZACYCLES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO., INC. (US) 1998-06-18 — — WO disclosed
US-5652235-A Method of using spiro piperidines to promote the release of growth hormone MERCK & CO., INC. (US) 1997-07-29 — — US disclosed
US-5536716-A Spiro piperidines and homologs which promote release of growth hormone MERCK & CO., INC. (US) 1996-07-16 — — US disclosed
EP-0702681-A1 SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS MERCK & CO. INC. (US) 1996-03-27 — — EP disclosed
WO-1994029309-A1 SPIRO-SUBSTITUTED AZACYCLES AS NEUROKININ ANTAGONISTS MERCK & CO., INC. (US) 1994-12-22 — — WO disclosed
EP-0615977-A1 Spiro piperidines and homologs which promote release of growth hormone MERCK & CO. INC. (US) 1994-09-21 — — EP disclosed
WO-1994013696-A1 SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 1994-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250215012-A1 IKZF2 DEGRADERS AND USES THEREOF IKZF1, IKZF2, IKZF3 USP2 251/4885SMN1; SMN2 2807/4885ESR2 2299/4885
US-20250195484-A1 CEREBLON LIGANDS AND USES THEREOF CRBN, CDR2, CHLSN USP2 58/4885SMN1; SMN2 1764/4885ESR2 1282/4885
US-20250122171-A1 Substituted Amine Compounds, Compositions and Methods of Use MRGPRX2, MRGPRX1, MRGPRX4 USP2 4037/4885SMN1; SMN2 1078/4885ESR2 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.